All In Biotech

Drug Trial Radar · NCT04943848

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

A Phase I Clinical Trial of Neo-antigen Heat Shock Protein Vaccine (rHSC-DIPGVax) in Combination With Checkpoint Blockade for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma in Childhood

Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jan 10, 2022

Primary completion

Sep 2026

Study completion Sep 2027

Sponsor

Lead sponsor
Ann & Robert H Lurie Children's Hospital of ChicagoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Dana-Farber Cancer Institute; Children's Hospital of Orange County; University of Calgary
First posted
Jun 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes found in the majority of DIPG and DMG tumors. Newly diagnosed patients with DIPG and DMG who have completed radiation six to ten weeks prior to enrollment are eligible.

Conditions

  • Diffuse Intrinsic Pontine Glioma
  • Diffuse Midline Glioma, H3 K27M-Mutant

Interventions

  • rHSC-DIPGVaxBiological

    Off-the-shelf, neoantigen heat shock protein vaccine

  • BalstilimabDrug

    BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)

  • ZalifrelimabDrug

    ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability: Dose limiting toxicities of rHSC-DIPGVaxTime frame: DLT period of 28 days for rHSC-DIPGVax monotherapy
  2. Safety and Tolerability: Dose limiting toxicities of rHSC-DIPGVax plus BALSTILIMABTime frame: DLT period of 28 days for Part A
  3. Safety and Tolerability: Dose limiting toxicities of rHSC-DIPGVax plus BALSTILIMAB and ZALIFRELIMABTime frame: DLT period of 42 days for Part B

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Health Orange County (CHOC)

    Orange, California · Recruiting

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Dana-Farber Boston Children's Cancer and Blood Disorders Center

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.